Thierry Gorlia

56.3k total citations · 7 hit papers
158 papers, 31.2k citations indexed

About

Thierry Gorlia is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Thierry Gorlia has authored 158 papers receiving a total of 31.2k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Genetics, 75 papers in Pulmonary and Respiratory Medicine and 34 papers in Oncology. Recurrent topics in Thierry Gorlia's work include Glioma Diagnosis and Treatment (117 papers), Brain Metastases and Treatment (52 papers) and Radiomics and Machine Learning in Medical Imaging (23 papers). Thierry Gorlia is often cited by papers focused on Glioma Diagnosis and Treatment (117 papers), Brain Metastases and Treatment (52 papers) and Radiomics and Machine Learning in Medical Imaging (23 papers). Thierry Gorlia collaborates with scholars based in Belgium, Netherlands and France. Thierry Gorlia's co-authors include Roger Stupp, Michael Weller, Martin J. van den Bent, J. Gregory Cairncross, R.O. Mirimanoff, Warren Mason, Robert C. Janzer, Alba A. Brandes, Martin Taphoorn and Anouk Allgeier and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Thierry Gorlia

144 papers receiving 30.8k citations

Hit Papers

Radiotherapy plus Concomitant and Adjuvant Temozolomide f... 2005 2026 2012 2019 2005 2005 2007 2012 2008 5.0k 10.0k 15.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
    2005 16.0k citations Roger Stupp, Warren Mason et al. profile →
  2. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
    2005 5.2k citations Monika E. Hegi, Thierry Gorlia et al. profile →
  3. Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
    2007 1.2k citations Thierry Gorlia et al. profile →
  4. Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
    2012 804 citations Martin J. van den Bent, Alba A. Brandes et al. Journal of Clinical Oncology profile →
  5. Stem Cell–Related “Self-Renewal” Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma
    2008 566 citations Thierry Gorlia, Wolfgang Wick et al. Journal of Clinical Oncology profile →
  6. Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
    2006 523 citations Martin J. van den Bent, Alba A. Brandes et al. Journal of Clinical Oncology profile →
  7. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas
    2011 401 citations Martin J. van den Bent, Thierry Gorlia et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thierry Gorlia Belgium 46 20.6k 10.3k 8.1k 7.3k 5.4k 158 31.2k
Alba A. Brandes Italy 62 23.6k 1.1× 10.1k 1.0× 9.7k 1.2× 7.5k 1.0× 6.6k 1.2× 359 34.1k
Warren Mason Canada 49 20.5k 1.0× 10.6k 1.0× 7.6k 0.9× 6.8k 0.9× 5.7k 1.1× 219 33.3k
Timothy F. Cloughesy United States 91 20.4k 1.0× 10.9k 1.1× 6.5k 0.8× 7.8k 1.1× 6.3k 1.2× 557 33.6k
R.O. Mirimanoff Switzerland 30 16.4k 0.8× 8.3k 0.8× 6.9k 0.8× 5.7k 0.8× 4.5k 0.8× 71 26.4k
David A. Reardon United States 89 20.8k 1.0× 10.4k 1.0× 7.3k 0.9× 7.2k 1.0× 8.7k 1.6× 560 34.0k
J. Gregory Cairncross Canada 60 24.9k 1.2× 12.5k 1.2× 9.4k 1.2× 8.4k 1.1× 5.9k 1.1× 169 36.1k
Quinn T. Ostrom United States 48 17.2k 0.8× 9.3k 0.9× 6.4k 0.8× 6.0k 0.8× 3.9k 0.7× 154 31.1k
Christine Marosi Austria 46 14.7k 0.7× 7.2k 0.7× 5.6k 0.7× 4.8k 0.7× 4.5k 0.8× 196 24.4k
Mark R. Gilbert United States 77 15.1k 0.7× 6.6k 0.6× 6.8k 0.8× 4.5k 0.6× 5.9k 1.1× 491 24.8k
Michael D. Prados United States 90 18.8k 0.9× 7.9k 0.8× 7.4k 0.9× 4.6k 0.6× 4.9k 0.9× 418 27.6k

Countries citing papers authored by Thierry Gorlia

Since Specialization
Citations

This map shows the geographic impact of Thierry Gorlia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thierry Gorlia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thierry Gorlia more than expected).

Fields of papers citing papers by Thierry Gorlia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thierry Gorlia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thierry Gorlia. The network helps show where Thierry Gorlia may publish in the future.

Co-authorship network of co-authors of Thierry Gorlia

This figure shows the co-authorship network connecting the top 25 collaborators of Thierry Gorlia. A scholar is included among the top collaborators of Thierry Gorlia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thierry Gorlia. Thierry Gorlia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Albert, Nathalie L., Émeline Tabouret, Émilie Le Rhun, et al.. (2025). TIP-01. [177Lu]Lu-DOTATATE for recurrent meningioma (LUMEN-1, EORTC-2334-BTG): study protocol for a randomized phase II trial. Neuro-Oncology. 27(Supplement_5). v419–v420.
2.
Geurts, Marjolein, Franz Koenig, Burt Nabors, et al.. (2025). Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: Does time of administration matter?. Neuro-Oncology Practice. 12(2). 291–300. 1 indexed citations
3.
Rhun, Émilie Le, Sara Erridge, David A. Reardon, et al.. (2025). Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma. JAMA Network Open. 8(11). e2545578–e2545578.
4.
Tabouret, Émeline, Julia Furtner, Thomas Graillon, et al.. (2024). 3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas. Neuro-Oncology. 26(7). 1302–1309. 2 indexed citations
5.
Coomans, Marijke B, Linda Dirven, Neil K. Aaronson, et al.. (2022). Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period. Neuro-Oncology. 24(12). 2159–2169. 13 indexed citations
6.
Rhun, Émilie Le, Felix Boakye Oppong, Roger Stupp, et al.. (2022). Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. Neuro-Oncology. 24(9). 1533–1545. 14 indexed citations
7.
Rhun, Émilie Le, Felix Boakye Oppong, Martin J. van den Bent, et al.. (2022). Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101. European Journal of Cancer. 178. 13–22. 10 indexed citations
8.
Schell, Marianne, Gianluca Brugnara, Fabian Isensee, et al.. (2020). Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. Neuro-Oncology. 22(11). 1667–1676. 9 indexed citations
9.
Coomans, Marijke B, Martin Taphoorn, Neil K. Aaronson, et al.. (2020). Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients. Neuro-Oncology Practice. 7(6). 668–675. 8 indexed citations
10.
Keßler, Tobias, Anne Berberich, Ahmed Sadik, et al.. (2020). Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. Cancer Medicine. 9(22). 8373–8385. 14 indexed citations
11.
Furtner, Julia, Thierry Gorlia, Martin Bendszus, et al.. (2019). Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. Neuro-Oncology. 21(12). 1587–1594. 66 indexed citations
12.
French, Pim J., Marica Eoli, Juan Manuel Sepúlveda-Sánchez, et al.. (2019). Defining EGFR amplification status for clinical trial inclusion. Neuro-Oncology. 21(10). 1263–1272. 28 indexed citations
13.
Hegi, Monika E., Thierry Gorlia, Roger Stupp, et al.. (2018). MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. Clinical Cancer Research. 25(6). 1809–1816. 90 indexed citations
14.
Rhun, Émilie Le, Roger Stupp, Olivier Chinot, et al.. (2018). Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. European Journal of Cancer. 101. 95–104. 10 indexed citations
15.
Bent, Martin J. van den, Lale Erdem‐Eraslan, Ahmed Idbaïh, et al.. (2013). MGMT -STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951. Clinical Cancer Research. 19(19). 5513–5522. 95 indexed citations
16.
Bent, Martin J. van den, Alba A. Brandes, Martin Taphoorn, et al.. (2012). Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology. 31(3). 344–350. 804 indexed citations breakdown →
17.
Bent, Martin J. van den, Alba A. Brandes, Martin Taphoorn, et al.. (2012). LONG-TERM FOLLOW-UP OF EORTC 26951, A RANDOMIZED TRIAL ON ADJUVANT PCV CHEMOTHERAPY IN ANAPLASTIC OLIGODENDROGLIAL TUMORS. A REPORT OF THE EORTC BTG.. Data Archiving and Networked Services (DANS).
18.
Bent, Martin J. van den, Lonneke A.M. Gravendeel, Thierry Gorlia, et al.. (2011). A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951. Clinical Cancer Research. 17(22). 7148–7155. 83 indexed citations
19.
Agnihotri, Sameer, Aaron S. Gajadhar, Thierry Gorlia, et al.. (2011). Alkylpurine–DNA–N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. Journal of Clinical Investigation. 122(1). 253–266. 137 indexed citations
20.
Bent, Martin J. van den, Hendrikus J. Dubbink, Yannick Marie, et al.. (2010). IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research. 16(5). 1597–1604. 304 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alba A. Brandes Breakdown of academic impact, for papers by Warren Mason Breakdown of academic impact, for papers by Timothy F. Cloughesy Breakdown of academic impact, for papers by R.O. Mirimanoff Breakdown of academic impact, for papers by David A. Reardon Breakdown of academic impact, for papers by J. Gregory Cairncross Breakdown of academic impact, for papers by Quinn T. Ostrom Breakdown of academic impact, for papers by Christine Marosi Breakdown of academic impact, for papers by Mark R. Gilbert Breakdown of academic impact, for papers by Michael D. Prados
Rankless by CCL
2026